New Technologies are the Driving Factor for the Hospital Acquired Infection Market

ROCKVILLE, Md., March 6, 2017 /PRNewswire/ — According to Kalorama Information, the global hospital acquired infection control market was worth about $16.0 billion in 2016. This market focuses on nosocomial infections, infections that develop in patients during hospitalization or during stays at health facilities. The market figure includes testing products, device sterilization, specific cleaning products, and HAI treatments. The healthcare market research firm’s report, Hospital Acquired Infection (HAI) Control Markets, provides market analysis for the prevention, diagnosis, and treatment segments of such infections.

“The infection control market is a probable growth market for some time,” said Bruce Carlson, Publisher of Kalorama Information. “There will always be a need to control these infections, as many of the bacteria that cause infection evolve and develop resistance to antimicrobials. New approaches to preventing, diagnosing, and treating such infections will be required for the long-term.”

The U.S. Department of Health and Human Services (HHS) is committed to reducing the national rate of HAIs by demonstrating significant, quantitative, and measurable reductions in Catheter-Associated Urinary Tract Infection (CAUTI), Central Line-associated Bloodstream Infections (CLABSI), Clostridium difficile (“C. diff”), methicillin-resistant Staphylococcus aureus (MRSA), and surgical site infections.

The prevention segment of the HAI control market encompasses both sterilization and disinfection equipment.  There is a growing trend for department-wide treatments and a revolving replacement rate is continuing to generate market stability.  The rate of replacement for typical steam, heat or chemical sterilizers is between 8 and 11 years, which offers a stable replacement sales base.  New technologies are a driving factor for growth, with increasing interest in wide-area sterilizing and disinfecting programs.

Diagnosis – testing for nosocomial infections – is a fast-growing market segment.  The increased awareness of infections is improving sales for the segment; admission screening and susceptibility testing are become popular choices for reducing infection risks.

The treatment segment of the HAI control market has struggled to maintain growth with a weak development pipeline, growing generic product introductions, and growing resistance problems.  However, more advanced products effective at treating serious infections demand a higher price, which is continuing to offset some challenges in the market.

Kalorama Information’s Hospital Acquired Infection (HAI) Control Markets provides market estimates and forecasts of the markets for the prevention, testing, and treatment of infections in healthcare surroundings, including the world revenues for 2010-2021 for hospital infection control, for hospital infection treatment, and for hospital infection prevention equipment and consumables (sterilization/disinfection).  Sales information is also provided for the different market segments by primary geographic region (United States, Europe, rest of world) and leading manufacturers’ shares.  Merck, Pfizer, GlaxoSmithKline, and Bayer – key companies in HAI control markets – are among those manufacturers featured in the report’s competitor analysis.

View the full abstract and purchase the report here:

About Kalorama Information
Kalorama Information, a division of, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama’s website and are also available on and

We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog on our company website.

Please link any media or news references to our reports or data to

Press Contact:
Bruce Carlson
212 807 2262
[email protected]

SOURCE Kalorama Information

Related Links

Press Release originally published at PRWEB.Com on March 6, 2017